LAVAL, Quebec—April 13, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.
Presentation Details:
Event: Bloom Burton & Co. Healthcare Investor Conference
Date/Time: Tuesday, April 20, 2021 at 2:00 p.m. ET
A live webcast of the presentation may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.
Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.
Chronic pruritus associated with atopic dermatitis is an irritating sensation that leads to scratching and persists for longer than 6 weeks in atopic dermatitis patients. It is estimated that 5% of adults in the United States suffer from atopic dermatitis – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting atopic dermatitis, there continues to be a lack of options targeting the burden of pruritus in patients with atopic dermatitis.
FOR MORE INFORMATION, PLEASE CONTACT:
Danny Matthews
Director, Investor Relations and Communications
danny@bellushealth.com
Recent BLU News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/30/2024 03:56:14 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 08/14/2023 09:01:58 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/10/2023 12:00:11 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 06/28/2023 09:21:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 06:42:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 03:05:50 PM
- Annonce boursière - Réservée aux médias et aux investisseurs - GSK mène à terme l'acquisition de BELLUS Santé • PR Newswire (Canada) • 06/28/2023 02:59:00 PM
- Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health • PR Newswire (Canada) • 06/28/2023 02:57:00 PM
- BELLUS Santé inc. annonce les résultats du vote tenu à l’assemblée extraordinaire des actionnaires • Business Wire • 06/16/2023 05:50:00 PM
- BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders • Business Wire • 06/16/2023 05:50:00 PM
- BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK • Business Wire • 05/16/2023 09:01:00 PM
- BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition • Business Wire • 05/16/2023 09:01:00 PM
- BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023 • Business Wire • 05/12/2023 08:01:00 PM
- BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights • Business Wire • 05/12/2023 08:01:00 PM
- BELLUS Santé annonce de l’information récente au sujet de l’assemblée • Business Wire • 04/26/2023 10:00:00 PM
- BELLUS Health Announces Meeting Updates • Business Wire • 04/26/2023 10:00:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM